GlobeNewswire

In July revenues increased by 14%, significant growth in all the main markets

Share

JSC Olainfarm preliminary consolidated results for July 2019 indicate that revenues increased by 14% compared to the same month last year and reached 9.5 million euro. At the same time consolidated results for the first seven months of 2019 show that revenues reached 75.9 million euro which is an increase by 8%, compared to the seven-month period of 2018. Positive tendencies are observed in all the main markets – Latvia, Russia, Belarus and Ukraine. Products of Olainfarm Group during this period were sold in 54 markets worldwide.

Consolidated sales in July show that historical major markets (Latvia, Russia, Ukraine and Belarus) had significant increase over July last year, where revenues in Latvia rose by 27%, in Russia by 9%, in Ukraine and Belarus by 26% and 42%, respectively. Sale of products also increased in Italy (by 1153%), in Turkmenistan (by 75%), in Moldova (by 46%) and in the Netherlands (by 62%). Out of the ten largest markets revenues declined only in Kazakhstan (by 42%) and in Germany (by 17%).

In the first seven months of 2019, the main sales markets of Olainfarm Group continued to contribute 78% of the total revenue – Latvia (29% share), Russia (27% share), Belarus (13% share) and Ukraine (9% share). Other major sales markets included Kazakhstan, Uzbekistan, the Netherlands, Germany, Tajikistan and Lithuania. The most rapid sales growth during this seven-month period was achieved in the Netherlands, where sales grew by 481% compared to the last year, and in Tajikistan where sales grew by 29%. Sales in Latvia improved by 13%, in Russia by 3%, in Belarus by 10% but in Uzbekistan by 21%. Amongst the largest sales outlets a decline was marked in Ukraine (-2%), in Kazakhstan (-2%), Germany (-7%) and Lithuania (-28%).

“The most recent sales data for July indicates significant increase, including in such target markets as Latvia and Russia. It shows wider picture about situation in the company and confirms that chosen development path  is successful. Olainfarm’s management team carefully analyses situation in strategic markets and we can confirm that short-term revenue drop in June was related to practical short-term factors on our partners’ side, and we continue to head according to the plan with confidence,” emphasizes Lauris Macijevskis, Chairman of the Board of JSC Olainfarm.

July 2019, consolidated sales   Sales, thous. EUR Share in total sales Changes to July 2018
Latvia 3 170 33% 27%
Russia 2 707 28% 9%
Ukraine 1 008 11% 26%
Belarus 893 9% 42%
Kazakhstan 209 2% -42%
Italy 133 1% 1153%
Turkmenistan 122 1% 75%
Germany 119 1% -17%
Moldova 118 1% 46%
The Netherlands 116 1% 62%
Other 937 10% -24%
Total 9 533 100% 14%


7 months 2019, consolidated sales Sales, thous. EUR Share in total sales Changes to 7 months 2018
Latvia 22 230 29% 13%
Russia 20 448 27% 3%
Belarus 9 818 13% 10%
Ukraine 6 760 9% -2%
Kazakhstan 1 845 2% -2%
Uzbekistan 1 835 2% 21%
The Netherlands 1 666 2% 481%
Germany 1 135 1% -7%
Tajikistan 1 058 1% 29%
Lithuania 820 1% -28%
Other 8 245 11% 4%
Total 75 859 100% 8%

Unconsolidated sales – July and 7 months

According to preliminary unconsolidated figures, JSC Olainfarm sales reached 7 million euros in July, which represents an increase by 16% compared to July, 2018. Sale of products improved in Russia (+21%), Latvia (+18%), Ukraine (+25%), Belarus (+71%), Italy (+1153%), Turkmenistan (+75%) and in the Netherlands (+62%). The decline was observed Germany by 19% and in Poland by 31%. In July India was among the major markets.

The unconsolidated sales results for the first seven months of 2019 show that JSC Olainfarm sales reached 57.4 million euros, which represents an increase by 7% compared to the first 7 months of 2018. During this reporting period, sales have increased in seven out of the ten major markets of Olainfarm – Russia (+6%), Latvia (+2%), Belarus (+9%), Uzbekistan (+21%), the Netherlands (+483%), Tajikistan (+252%) and in Italy (+28%). Revenues declined by 1% in Ukraine, by 7% in Germany and by 23% in Kazakhstan.

July 2019, unconsolidated sales Sales, thous. EUR Share in total sales Changes to July 2018
Russia 2 522 36% 21%
Latvia 1 416 20% 18%
Ukraine 978 14% 25%
Belarus 847 12% 71%
Italy 133 2% 1153%
Turkmenistan 122 2% 75%
Germany 116 2% -19%
The Netherlands 116 2% 62%
India 109 2% N/A
Poland 105 1% -31%
Other 565 8% -46%
Total 7 029 100% 16%


Seven months 2019 unconsolidated sales Sales, thous. EUR Share in total sales Changes to seven months 2018
Russia 18 562 32% 6%
Latvia 10 004 17% 2%
Belarus 8 153 14% 9%
Ukraine 6 645 12% -1%
Uzbekistan 1 835 3% 21%
The Netherlands 1 666 3% 483%
Germany 1 125 2% -7%
Tajikistan 1 005 2% 252%
Kazakhstan 987 2% -23%
Italy 746 1% 28%
Other 6 714 12% -8%
Total 57 441 100% 7%

Results of subsidiaries – July and the first seven months of 2019

The pharmacy chain Ltd. Latvijas Aptieka sales reached 2.1 million euros in July 2019, which represents a 16% increase compared to July 2018. 68 pharmacies were operating during this period. Ltd. Silvanols sales reached 0.2 million euros in July 2019, representing a decline by 11% vs. July 2018. The combined sales of Tonus Elast and Elast Medical in July 2019 were 1.03 million euros, which is by 14% more than this time last year. Olainmed and Diamed Medical Center sales reached 0.27 million euros, while the Belarus subsidiary NPK Biotest reached 0.21 million euros in sales in July that is higher by 59% than in July last year.

During the first seven month period of 2019, Ltd. Latvijas Aptieka sales amounted to 15.0 million euros, demonstrating a 7% increase in comparison to the same time period last year, sales of Ltd. Silvanols reached 3.2 million euros which is 3% less than last year. The combined sales of Tonus Elast and Elast Medical during the seven months this year totaled 5.6 million euros which is an increase by 4%. Medical Centers Diamed and Olainmed revenues were 1.8 million euros during the first seven months of this year and the Belarus company NPK Biotest sales were worth 1.7 million euros, improving the result of the last year by 36%.

  July 2019 7 months 2019
Sales markets of Olainfarm 46 47
Sales markets of the Group 53 54
Number of pharmacies 68  
Sales of Latvijas Aptieka, thous. EUR 2 060 15 028
Sales of Medical centers, thous. EUR 266 1 802
Sales of NPK Biotest, thous. EUR 211 1 726
Sales of Tonus Elast and Elast Medical, thous. EUR 1 025 5 564
Sales of Silvanols, thous. EUR 208 3 169

According to the JSC Olainfarm budget, unconsolidated sales are planned to reach 99 million euros in 2019, while consolidated sales are expected at 133 million euros.  According to these preliminary sales figures, in the first six months of 2019, 58% of annual target for unconsolidated sales and 57% of annual target for consolidated sales have been reached.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top-quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Additional information:
       
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Ph.: +371 29178878
janis.dubrovskis@olainfarm.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

NAXS Delårsrapport januari – september 201918.10.2019 17:45:00 CESTPressemelding

Nio månader 2019 Resultat efter skatt uppgick till 26,4 (22,2) MSEK. Resultatet per aktie uppgick till 2,29 (1,70) SEK. Substansvärdet uppgick till 717 MSEK (SEK 64,16 per aktie) per den 30 september 2019, jämfört med 736 MSEK (SEK 61,81 per aktie) per den 31 december 2018. De omfattande aktieåterköpen under delårsperioden samt betalning av utdelningen för 2018 var de två viktigaste orsakerna till det minskade substansvärdet. Nettokassan uppgick till 194 MSEK (17,40 SEK per aktie) per den 30 september 2019, jämfört med 261 MSEK (21,94 SEK per aktie) per den 31 december 2018. Årsstämman 2019 beslutade att lämna en utdelning om 2,78 SEK per aktie. Tredje kvartalet 2019 Resultat efter skatt uppgick till 11,7 (10,6) MSEK. Resultatet efter skatt per aktie uppgick till 1,05 (0,86) SEK. VD-kommentar NAXS hade en fortsatt stabil utveckling under det tredje kvartalet med en tillväxt i substanse/aktie om 3% under kvartalet och 7,4% över en 12-månaders period, inklusive lämnad utdelning. NAXS har

Interim Report January-September 201918.10.2019 17:45:00 CESTPress release

Nine months 2019 Net profit/loss for the period amounted to MSEK 26.4 (22.2). Earnings per share amounted to SEK 2.29 (1.70). Net asset value amounted to MSEK 717 (SEK 64.16 per share) at September 30, 2019, compared to MSEK 736 (SEK 61.81 per share) at year-end 2018. The fact that the total net asset value decreased, while the net asset value per share increased is due to the shares repurchases made during the period. Net cash amounted to MSEK 194 (SEK 17.40 per share) at September 30, 2019, compared to MSEK 261 (SEK 21.94 per share) at year-end 2018. The 2019 Annual General Meeting resolved that a dividend of 2.78 SEK per share to the shareholders for FY 2018. Third quarter 2019 Net profit/loss for the quarter amounted to MSEK 11.7 (10.6). Earnings per share amounted to SEK 1.05 (0.86). Comments by the CEO NAXS delivered a steady performance during the third quarter of 2019, with the NAV/share growing by 3% during the quarter and by 7.4% over 12 months, including the dividend paid. N

DNO ASA: Mandatory Notification of Trade18.10.2019 16:47:00 CESTPress release

Oslo, 18 October 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,200,000 own shares at an average price of NOK 12.4482 per share. Following this transaction, DNO holds 78,800,000 own shares. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

PCI Biotech: Mandatory notification regarding trade of shares18.10.2019 14:59:00 CESTPress release

Stocken Invest AS, a wholly owned company by Lars Viksmoen, has on 18 October 2019 transferred 12,966 shares in PCI Biotech Holding ASA (“PCI Biotech”) to Lars Viksmoen, board member of PCI Biotech, at an average price of NOK 26.80 per share. After the transaction, Lars Viksmoen holds 12,966 shares in PCI Biotech and Stocken Invest AS holds 0 shares in PCI Biotech. This information is subject to the disclosure requirements pursuant to section 4-2 of the Norwegian Securities Trading Act.

Announcement of the Management Board of joint stock company “Olainfarm”18.10.2019 14:23:00 CESTPress release

The joint stock company “Olainfarm” has received draft decisions prepared by the initiators of the November 1, 2019 Extraordinary General Meeting of Shareholders – limited liability company “OLMAFARM” and Andrejs Saveljevs who is authorized representative of Nika Saveljeva, which include, inter alia, a list of candidates for the Council and Auditing committee of joints stock company “Olainfarm”. The requirements laid down in the laws and regulations in force in Republic of Latvia and in related documents determines the specific requirements to be complied with by capital companies listed in regulated market regarding their management and disclosure of information. Legislation of the Republic of Latvia (including the Financial Instrument Market Law) sets requirements for capital companies, and the European Union and the OECD (Organization for Economic Co-operation and Development) set out recommendations for the corporate governance of the capital companies. Nasdaq Riga, AS has develope

Nordic American Tankers Limited (NYSE:NAT) Announces the date for its 2019 Annual General Meeting of Shareholders (AGM)18.10.2019 13:32:00 CESTPress release

Hamilton, Bermuda, October 18, 2019. Nordic American Tankers Limited today announced that its Board of Directors has scheduled the 2019 AGM, to be held on November 20, 2019 at 10:00 a.m., local time, at the LOM Building,27 Reid Street, Hamilton HM 11 Bermuda. The Board has set a record date of October 8, 2019 for the determination of the NAT shareholders entitled to receive notice of and to vote at the AGM or any adjournment thereof. The Notice of the Meeting and Proxy Statement will be furnished to the Securities and Exchange Commission (SEC) on October 18, 2019. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals,